Evidence map›Paper›PMID 36589752›Full record

ArticleFrontiers in cell and developmental biology2022

Detection of

Ning Li, Zhiqin Chen, Mei Huang, Ding Zhang, Mengna Hu, Feng Jiao, Ming Quan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.International journal of molecular sciences · 2023
    Review
  7. Progress of non-small-cell lung cancer withFrontiers in molecular biosciences · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ning LiDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiqin ChenDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Mei HuangDepartment of Oncology, Yancheng Third People's Hospital, Yancheng, China.
Ding ZhangThe Medical Department, 3D Medicines Co., Ltd., Shanghai, China.
Mengna HuThe Medical Department, 3D Medicines Co., Ltd., Shanghai, China.
Feng JiaoDepartment of Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Ming QuanDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai East Hospital · CNShanghai First People's Hospital · CNShanghai Jiao Tong University · CNYancheng Third People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

lung cancernext-generation sequencingROS1 breakpointROS1 fusions partnerssolid tumor

Identifiers

PMID36589752
PMCPMC9798300
OpenAlexW4311792724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.